AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19809604 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic thromboprophylaxis with low‐molecular‐weight heparins, vitamin K antagonists, or fondaparinux
Number of subjects: 0
Study 16996338 — intervention group
Group type: EXPERIMENTAL
Intervention: L-EUS
Number of subjects: 43
Study 16996338 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-EUS
Number of subjects: 43
Study 16996338 — intervention group
Group type: EXPERIMENTAL
Intervention: FNA (performed in 16 of the 27 subjects)
Number of subjects: 43
Study 14584962 — intervention group
Group type: EXPERIMENTAL
Intervention: Deramciclane 30 mg intravenous administration
Number of subjects: 12
Study 14584962 — intervention group
Group type: EXPERIMENTAL
Intervention: Deramciclane oral administration (solution)
Number of subjects: 12
Study 14584962 — intervention group
Group type: EXPERIMENTAL
Intervention: Deramciclane oral administration (tablet)
Number of subjects: 12
Study 15105065 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum, multicomponent intervention (counseling, videotape about OCs, written material)
Number of subjects: 43
Study 15105065 — intervention group
Group type: COMPARATOR
Intervention: Usual care (resident-physician counseling)
Number of subjects: 43
Study 15105065 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum, multicomponent intervention
Number of subjects: 43
Study 10405887 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐PCR detection of rotaviruses
Number of subjects: 2398
Study 10405887 — intervention group
Group type: COMPARATOR
Intervention: G2 rotaviruses
Number of subjects: 2398
Study 10405887 — intervention group
Group type: COMPARATOR
Intervention: G4 rotaviruses
Number of subjects: 2398
Study 7599448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride treatment (75 mg NaF/day)
Number of subjects: 43
Study 7599448 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 43
Study 2223336 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation (HFJV) at a driving pressure of 1 bar
Number of subjects: 0
Study 2223336 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation (HFJV)
Number of subjects: 0
Study 360272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administered as a bolus intra-arterially prior to contrast media injections
Number of subjects: 30
Study 360272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine mixed with contrast agent (2 mgm of lidocaine with each ml of contrast agent)
Number of subjects: 30
Study 360272 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 31985352 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet for 4 days before the second run
Number of subjects: 11
Study 31985352 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified in detail)
Number of subjects: 11
Study 30824252 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-facilitated TF-CBT
Number of subjects: 27
Study 30824252 — intervention group
Group type: COMPARATOR
Intervention: Standard TF-CBT
Number of subjects: 27
Study 28382880 — intervention group
Group type: EXPERIMENTAL
Intervention: Head elevation (HE)
Number of subjects: 22
Study 28382880 — intervention group
Group type: EXPERIMENTAL
Intervention: External laryngeal manipulation (ELM)
Number of subjects: 22
Study 28382880 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward laryngoscope traction (FT)
Number of subjects: 22
Study 28382880 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjunctive maneuvers)
Number of subjects: 22
Study 25223583 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 (cytarabine: daunorubicin) liposome injection
Number of subjects: 125
Study 25223583 — intervention group
Group type: COMPARATOR
Intervention: Control salvage treatment (investigators' choice of first salvage chemotherapy)
Number of subjects: 125
Study 25299476 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine functional restoration program (5 weeks)
Number of subjects: 134
Study 21112101 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 525
Study 21112101 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 525
Study 19304046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonroutine (NR group) postoperative instructions, including education on the possibility of mandibular fracture and emphasis on a soft diet for 4 weeks.
Number of subjects: 560
Study 19304046 — intervention group
Group type: COMPARATOR
Intervention: Routine (R group) postoperative instructions, with no education or emphasis on diet.
Number of subjects: 560
Study 17329347 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Stress Index (SSI) computed from normalized heart beat interval (HBI(norm)) and plethysmographic pulse wave amplitude (PPGA(norm)).
Number of subjects: 60
Study 15370939 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation/Action stages of change
Number of subjects: 499
Study 15370939 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemplation Ladder ratings between 8 and 10
Number of subjects: 499
Study 15370939 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models
Number of subjects: 499
Study 11349750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail service pharmacies
Number of subjects: 2437
Study 11349750 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional chain store pharmacies
Number of subjects: 2437
Study 11349750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital pharmacies
Number of subjects: 2437
Study 11349750 — intervention group
Group type: COMPARATOR
Intervention: Independent community pharmacies
Number of subjects: 2437
Study 11349750 — intervention group
Group type: COMPARATOR
Intervention: Home health care
Number of subjects: 2437
Study 11349750 — intervention group
Group type: COMPARATOR
Intervention: Grocery chain store pharmacies
Number of subjects: 2437
Study 11349750 — intervention group
Group type: COMPARATOR
Intervention: Mass merchandise chain store pharmacies
Number of subjects: 2437
Study 11349750 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall relationship between prescription orders filled/hour and risk of dispensing errors
Number of subjects: 2437
Study 11349750 — intervention group
Group type: EXPERIMENTAL
Intervention: Job satisfaction variables
Number of subjects: 2437
Study 9879390 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 9879390 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 7517531 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD pacing at AV interval of 100 msec
Number of subjects: 12
Study 7517531 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD pacing at AV interval of 60 msec
Number of subjects: 12
Study 7517531 — intervention group
Group type: COMPARATOR
Intervention: Control (sinus rhythm)
Number of subjects: 12
Study 2566778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg twice daily)
Number of subjects: 1072
Study 2566778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study 2566778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 1072
Study 31165647 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga for Cancer Survivors (YOCAS)
Number of subjects: 410
Study 31165647 — intervention group
Group type: COMPARATOR
Intervention: Standard survivorship care
Number of subjects: 410
Study 27751801 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched readymade meals and protein-enriched bread (5 meals and plentiful bread for 2 weeks)
Number of subjects: 42
Study 27751801 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched readymade meals and protein-enriched bread
Number of subjects: 42
Study 27751801 — intervention group
Group type: COMPARATOR
Intervention: Regular equivalents (control group)
Number of subjects: 42
Study 27751801 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched products
Number of subjects: 42
Study 25537443 — intervention group
Group type: EXPERIMENTAL
Intervention: Genium knee
Number of subjects: 30
Study 25537443 — intervention group
Group type: COMPARATOR
Intervention: C-Leg knee
Number of subjects: 30
Study 25537443 — intervention group
Group type: COMPARATOR
Intervention: Non-amputee controls
Number of subjects: 30
Study 23559219 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic exposure
Number of subjects: 152
Study 23559219 — intervention group
Group type: COMPARATOR
Intervention: Control (no antipsychotic exposure)
Number of subjects: 152
Study 20622680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Sequential Compression Device (SCD)
Number of subjects: 66
Study 20622680 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study 19531453 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimmunochemotherapy (BCT) with cisplatin 20 mg/m² i.v. days 1,4; dacarbazine 800 mg/m² i.v. day 1; vinblastine 1.5 mg/m² i.v. days 1,4; IL-2 9 MIU/m² s.c. days 5,8; IFN-alpha-2b 5 MIU/m² s.c. days 5,8,11,13,15; supported by G-CSF and antibiotics
Number of subjects: 11
Study 18552034 — intervention group
Group type: EXPERIMENTAL
Intervention: Stammberger Sinus Dressing (SSD)
Number of subjects: 45
Study 18552034 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolvable Sinu‐Knit (DSK)
Number of subjects: 45
Study 18552034 — intervention group
Group type: COMPARATOR
Intervention: Routine Nasal Packing in Latex Gloves Finger (RNP)
Number of subjects: 45
Study 14695864 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific balance strategy training programme delivered in a workstation format
Number of subjects: 73
Study 14695864 — intervention group
Group type: COMPARATOR
Intervention: Community based exercise class programme (Control)
Number of subjects: 73
Study 11450888 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 617
Study 11450888 — intervention group
Group type: COMPARATOR
Intervention: Trovafloxacin
Number of subjects: 617
Study 9783758 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (7.5 mg once daily for 28 days)
Number of subjects: 8656
Study 9783758 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg once daily for 28 days)
Number of subjects: 8656
Study 8148289 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular lateral paravascular approach (SCLP)
Number of subjects: 40
Study 8148289 — intervention group
Group type: COMPARATOR
Intervention: Transarterial axillary approach
Number of subjects: 40
Study 3169753 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet about gonorrhoea
Number of subjects: 0
Study 3169753 — intervention group
Group type: COMPARATOR
Intervention: Control (no leaflet)
Number of subjects: 0
Study 30758214 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Joint Distraction (KJD)
Number of subjects: 114
Study 30758214 — intervention group
Group type: COMPARATOR
Intervention: Total Knee Arthroplasty (TKA)
Number of subjects: 114
Study 30758214 — intervention group
Group type: COMPARATOR
Intervention: High Tibial Osteotomy (HTO)
Number of subjects: 114
Study 31482613 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 6632
Study 28042979 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF and BMP-2
Number of subjects: 55
Study 28042979 — intervention group
Group type: COMPARATOR
Intervention: L-PRF alone
Number of subjects: 55
Study 25076119 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital TXA infusion
Number of subjects: 0
Study 25076119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23878368 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg trans-resveratrol
Number of subjects: 27
Study 23878368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 20808146 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (SSRI)
Number of subjects: 100
Study 20808146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17242667 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity
Number of subjects: 0
Study 17242667 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic disorders and inflammatory diseases
Number of subjects: 0
Study 16375658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg/day of divalproex sodium
Number of subjects: 20
Study 16375658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 mg/day of divalproex sodium
Number of subjects: 20
Study 16375658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11973443 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2/LNG (E2 0.045 mg/day with 0.030 and 0.040 mg/day LNG)
Number of subjects: 1138
Study 11973443 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2/LNG (E2 0.045 mg/day with 0.015, 0.030, and 0.040 mg/day LNG)
Number of subjects: 1138
Study 11973443 — intervention group
Group type: COMPARATOR
Intervention: Transdermal E2 0.045 mg/day
Number of subjects: 1138
Study 11973443 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2/LNG and E2
Number of subjects: 1138
Study 11973443 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2/LNG
Number of subjects: 1138
Study 9472187 — intervention group
Group type: EXPERIMENTAL
Intervention: AED
Number of subjects: 243
Study 9472187 — intervention group
Group type: COMPARATOR
Intervention: No AED
Number of subjects: 243
Study 17252658 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fluoride dentifrice (1450 ppm fluoride)
Number of subjects: 319
Study 17252658 — intervention group
Group type: COMPARATOR
Intervention: Low-fluoride dentifrice (250 ppm fluoride)
Number of subjects: 319
Study 2478428 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin, vinblastine, and bleomycin (PVB)
Number of subjects: 368
Study 2478428 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (refused adjuvant therapy)
Number of subjects: 368
Study 2478428 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 368
Study 2478428 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (no specific treatment mentioned)
Number of subjects: 368
Study 2478428 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (no specific treatment mentioned)
Number of subjects: 368
Study 824007 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined gamma rays and fast neutrons (mean energy 6 MeV)
Number of subjects: 257
Study 824007 — intervention group
Group type: COMPARATOR
Intervention: Low LET radiation alone (60Co gamma rays)
Number of subjects: 257
Study 30229847 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone intravenous analgesia
Number of subjects: 80
Study 30229847 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous analgesia
Number of subjects: 80
Study 26892991 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus-16/18 vaccination
Number of subjects: 2022
Study 25486677 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal experiences
Number of subjects: 28
Study 25486677 — intervention group
Group type: COMPARATOR
Intervention: Fact-oriented contributions
Number of subjects: 28
Study 23378397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smokers
Number of subjects: 80
Study 23378397 — intervention group
Group type: COMPARATOR
Intervention: Tobacco abstainers
Number of subjects: 80
Study 20063137 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic paravertebral block (SPVB)
Number of subjects: 36
Study 20063137 — intervention group
Group type: COMPARATOR
Intervention: Control (no block)
Number of subjects: 36
Study 18923570 — intervention group
Group type: EXPERIMENTAL
Intervention: C-DEF (exercise with energy balance but carbohydrate deficit)
Number of subjects: 10
Study 18923570 — intervention group
Group type: EXPERIMENTAL
Intervention: C-BAL (exercise with energy and carbohydrate balance)
Number of subjects: 10
Study 18923570 — intervention group
Group type: COMPARATOR
Intervention: BASE (no-exercise)
Number of subjects: 10
Study 16086617 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1-6 mg/day)
Number of subjects: 291
Study 16086617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 12756402 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 89
Study 11099601 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine inhalation challenge (group N-A)
Number of subjects: 205
Study 11099601 — intervention group
Group type: COMPARATOR
Intervention: Methacholine inhalation challenge (group N-N)
Number of subjects: 205
Study 11099601 — intervention group
Group type: COMPARATOR
Intervention: Methacholine inhalation challenge (group A-A)
Number of subjects: 205
Study 11099601 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Dmin-PO(2) between groups
Number of subjects: 205
Study 8628002 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower quadrant carcinoma
Number of subjects: 914
Study 8628002 — intervention group
Group type: COMPARATOR
Intervention: Other breast regions carcinoma
Number of subjects: 914
Study 1446287 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin pedicle skin flap
Number of subjects: 54
Study 3937508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 30569788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-drills training (BDT)
Number of subjects: 30
Study 30569788 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-sprint-ability training (RSAT)
Number of subjects: 30
Study 30569788 — intervention group
Group type: COMPARATOR
Intervention: General basketball training (Control)
Number of subjects: 30
Study 29589562 — intervention group
Group type: EXPERIMENTAL
Intervention: Annotated classification corpus of Chinese health questions (Qcorp)
Number of subjects: 5000
Study 27221806 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin added to metformin
Number of subjects: 0
Study 27221806 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea (SU)
Number of subjects: 0
Study 27221806 — intervention group
Group type: COMPARATOR
Intervention: Dipeptidyl-peptidase-4 inhibitor (DPP-4i)
Number of subjects: 0
Study 24299915 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant hypertension (res‐HTN)
Number of subjects: 17190
Study 23040575 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty
Number of subjects: 2095
Study 23040575 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty for BMS restenosis
Number of subjects: 2095
Study 23040575 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty for DES restenosis
Number of subjects: 2095
Study 23040575 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty for paclitaxel-eluting stent restenosis
Number of subjects: 2095
Study 23040575 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty for non-paclitaxel-eluting stent restenosis
Number of subjects: 2095
Study 23040575 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty for de novo lesions
Number of subjects: 2095
Study 23040575 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite vessel thrombosis
Number of subjects: 2095
Study 20812339 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (20 mg/day for 14 days)
Number of subjects: 20
Study 20812339 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no treatment)
Number of subjects: 20
Study 17599570 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's (LR)
Number of subjects: 80
Study 17599570 — intervention group
Group type: COMPARATOR
Intervention: Gelatin polysuccinate 4% (GF)
Number of subjects: 80
Study 16132799 — intervention group
Group type: EXPERIMENTAL
Intervention: High education level
Number of subjects: 542
Study 16132799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunburn episodes before age 15
Number of subjects: 542
Study 16132799 — intervention group
Group type: EXPERIMENTAL
Intervention: Light eye colour
Number of subjects: 542
Study 16132799 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar lentigines
Number of subjects: 542
Study 16132799 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of nevi >30
Number of subjects: 542
Study 16132799 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity to sunburn
Number of subjects: 542
Study 12407652 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% icodextrin
Number of subjects: 175
Study 12407652 — intervention group
Group type: COMPARATOR
Intervention: 2.5% dextrose
Number of subjects: 175
Study 10617012 — intervention group
Group type: EXPERIMENTAL
Intervention: EACA (5 g bolus, 2 g/h infusion, 2.5 g in priming)
Number of subjects: 210
Study 10617012 — intervention group
Group type: EXPERIMENTAL
Intervention: TA (1 g bolus, 400 mg/h infusion, 500 mg in priming)
Number of subjects: 210
Study 10617012 — intervention group
Group type: COMPARATOR
Intervention: AP (280 mg bolus, 70 mg/h infusion, 280 mg in priming)
Number of subjects: 210
Study 7581055 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation
Number of subjects: 28
Study 7581055 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 28
Study 1985413 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (20 mg/kg im soon after birth, and at 24 and 48 hours)
Number of subjects: 230
Study 1985413 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (single dose of 20 mg/kg)
Number of subjects: 230
Study 6189581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy for cerebral metastases
Number of subjects: 225
Study 6189581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy for headaches
Number of subjects: 225
Study 6189581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy for convulsions
Number of subjects: 225
Study 6189581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy for motor loss
Number of subjects: 225
Study 6189581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy for bone metastases in prostatic carcinoma
Number of subjects: 225
Study 6189581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy for bone metastases in renal primaries
Number of subjects: 225
Study 6189581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy for pain relief at eight weeks
Number of subjects: 225